103 related articles for article (PubMed ID: 28124285)
1. FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
Valla M; Engstrøm MJ; Ytterhus B; Hansen ÅK; Akslen LA; Vatten LJ; Opdahl S; Bofin AM
Breast Cancer Res Treat; 2017 Apr; 162(2):243-253. PubMed ID: 28124285
[TBL] [Abstract][Full Text] [Related]
2. MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.
Klæstad E; Opdahl S; Engstrøm MJ; Ytterhus B; Wik E; Bofin AM; Valla M
Breast Cancer Res Treat; 2020 Feb; 180(1):73-86. PubMed ID: 31950385
[TBL] [Abstract][Full Text] [Related]
3. Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases.
Valla M; Mjønes PG; Engstrøm MJ; Ytterhus B; Bordin DL; van Loon B; Akslen LA; Vatten LJ; Opdahl S; Bofin AM
J Histochem Cytochem; 2018 Nov; 66(11):787-799. PubMed ID: 30052477
[TBL] [Abstract][Full Text] [Related]
4. DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis.
Valla M; Opdahl S; Ytterhus B; Bofin AM
Breast Cancer Res Treat; 2021 May; 187(1):57-67. PubMed ID: 33616774
[TBL] [Abstract][Full Text] [Related]
5. ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes.
Klæstad E; Sawicka JE; Engstrøm MJ; Ytterhus B; Valla M; Bofin AM
Breast Cancer Res Treat; 2021 Feb; 186(1):65-77. PubMed ID: 33389351
[TBL] [Abstract][Full Text] [Related]
6. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation.
Lin CH; Liu JM; Lu YS; Lan C; Lee WC; Kuo KT; Wang CC; Chang DY; Huang CS; Cheng AL
J Clin Pathol; 2013 Feb; 66(2):140-5. PubMed ID: 23268322
[TBL] [Abstract][Full Text] [Related]
8. CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and Prognosis.
Valla M; Klæstad E; Ytterhus B; Bofin AM
J Mammary Gland Biol Neoplasia; 2022 Mar; 27(1):67-77. PubMed ID: 35459982
[TBL] [Abstract][Full Text] [Related]
9. HER2 gene copy number and breast cancer-specific survival.
Biserni GB; Engstrøm MJ; Bofin AM
Histopathology; 2016 Nov; 69(5):871-879. PubMed ID: 27271096
[TBL] [Abstract][Full Text] [Related]
10. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
11. PAK1 copy number in breast cancer-Associations with proliferation and molecular subtypes.
Skjervold AH; Valla M; Ytterhus B; Bofin AM
PLoS One; 2023; 18(6):e0287608. PubMed ID: 37368917
[TBL] [Abstract][Full Text] [Related]
12. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
13. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
14. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
15. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
[TBL] [Abstract][Full Text] [Related]
16. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
19. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
[TBL] [Abstract][Full Text] [Related]
20. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC
Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
